+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Monoclonal Antibodies Market Research Report by Source Type, by Indication, by End-User, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 5311207
  • Report
  • June 2021
  • Region: Global
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Monoclonal Antibodies Market Grew USD 179.06 Billion by 2026, at a CAGR of 12.22%

FEATURED COMPANIES

  • Abbott Laboratories
  • ADC Therapeutics
  • Astellas Pharma Inc
  • Biogen Idec Inc.
  • F. Hoffmann-La Roche AG
  • Mylan N.V.
  • MORE
The Global Monoclonal Antibodies Market size was estimated at USD 89.65 Billion in 2020 and expected to reach USD 100.30 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 12.22% from 2020 to 2026 to reach USD 179.06 Billion by 2026.



Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Monoclonal Antibodies to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Source Type, the Monoclonal Antibodies Market was examined across Chimeric, Human, Humanized, and Murine.
  • Based on Production Type, the Monoclonal Antibodies Market was examined across In Vitro and In Vivo.
  • Based on Indication, the Monoclonal Antibodies Market was examined across Autoimmune Diseases, Cancer, Infectious Diseases, Inflammatory Diseases, and Microbial Diseases.
  • Based on End-User, the Monoclonal Antibodies Market was examined across Hospitals and Research Institutes.
  • Based on Geography, the Monoclonal Antibodies Market was examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. The ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Monoclonal Antibodies Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Monoclonal Antibodies Market, including Abbott Laboratories, AbbVie, Inc, AbGenomics, ADC Therapeutics, ALMAC Group, Amgen Inc., Astellas Pharma Inc, AstraZeneca PLC, Bayer AG, Biogen Idec Inc., Bristol Myers Squibb, Daiichi Sankyo Company, Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, GenScript Biotech Corporation, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Mylan N.V., Novartis International AG, Novo Nordisk A/S, Pfizer Inc, Sanofi S.A., Seagen Inc., Shanghai Junshi Biosciences Co., Ltd., and Thermo Fisher Scientific, Inc.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Monoclonal Antibodies Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Monoclonal Antibodies Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Monoclonal Antibodies Market?
4. What is the competitive strategic window for opportunities in the Global Monoclonal Antibodies Market?
5. What are the technology trends and regulatory frameworks in the Global Monoclonal Antibodies Market?
6. What is the market share of the leading vendors in the Global Monoclonal Antibodies Market?
7. What modes and strategic moves are considered suitable for entering the Global Monoclonal Antibodies Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • ADC Therapeutics
  • Astellas Pharma Inc
  • Biogen Idec Inc.
  • F. Hoffmann-La Roche AG
  • Mylan N.V.
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. End-User Outlook
3.4. Indication Outlook
3.5. Production Type Outlook
3.6. Source Type Outlook
3.7. Geography Outlook
3.8. Competitor Outlook

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cost-efficient biosimilar monoclonal antibodies
5.1.1.2. Rising incidence of cancer and other chronic diseases
5.1.1.3. Increasing R&D activities in genomics coupled with the advent of technologically advanced genetic platforms
5.1.2. Restraints
5.1.2.1. Pricing of therapeutic mAbs are expensive
5.1.3. Opportunities
5.1.3.1. High adoption rate in developing countries
5.1.3.2. Substantial increase in the number of approvals per year
5.1.4. Challenges
5.1.4.1. Limitation in current manufacturing and purification processes (risk of contamination) affect production capacity and led to increasing cost
5.2. Cumulative Impact of COVID-19
5.3. Porters Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry

6. Monoclonal Antibodies Market, by Source Type
6.1. Introduction
6.2. Chimeric
6.3. Human
6.4. Humanized
6.5. Murine

7. Monoclonal Antibodies Market, by Production Type
7.1. Introduction
7.2. In Vitro
7.3. In Vivo

8. Monoclonal Antibodies Market, by Indication
8.1. Introduction
8.2. Autoimmune Diseases
8.3. Cancer
8.4. Infectious Diseases
8.5. Inflammatory Diseases
8.6. Microbial Diseases

9. Monoclonal Antibodies Market, by End-User
9.1. Introduction
9.2. Hospitals
9.3. Research Institutes

10. Americas Monoclonal Antibodies Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
10.6.1. California
10.6.2. Florida
10.6.3. Illinois
10.6.4. New York
10.6.5. Ohio
10.6.6. Pennsylvania
10.6.7. Texas

11. Asia-Pacific Monoclonal Antibodies Market
11.1. Introduction
11.2. China
11.3. India
11.4. Indonesia
11.5. Japan
11.6. Malaysia
11.7. Philippines
11.8. South Korea
11.9. Thailand

12. Europe, Middle East & Africa Monoclonal Antibodies Market
12.1. Introduction
12.2. France
12.3. Germany
12.4. Italy
12.5. Netherlands
12.6. Qatar
12.7. Russia
12.8. Saudi Arabia
12.9. South Africa
12.10. Spain
12.11. United Arab Emirates
12.12. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles
14.1. Abbott Laboratories
14.2. AbbVie, Inc
14.3. AbGenomics
14.4. ADC Therapeutics
14.5. ALMAC Group
14.6. Amgen Inc.
14.7. Astellas Pharma Inc
14.8. AstraZeneca PLC
14.9. Bayer AG
14.10. Biogen Idec Inc.
14.11. Bristol Myers Squibb
14.12. Daiichi Sankyo Company, Limited
14.13. Eli Lilly and Company
14.14. F. Hoffmann-La Roche AG
14.15. GenScript Biotech Corporation
14.16. GlaxoSmithKline PLC
14.17. Johnson & Johnson Services, Inc.
14.18. Merck & Co., Inc.
14.19. Mylan N.V.
14.20. Novartis International AG
14.21. Novo Nordisk A/S
14.22. Pfizer Inc
14.23. Sanofi S.A.
14.24. Seagen Inc.
14.25. Shanghai Junshi Biosciences Co., Ltd.
14.26. Thermo Fisher Scientific, Inc

15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
15.3. Contact Details

List of Tables
TABLE 1. GLOBAL MONOCLONAL ANTIBODIES MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 4. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY CHIMERIC, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 5. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMAN, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 6. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HUMANIZED, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 7. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY MURINE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 8. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 9. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VITRO, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 10. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY IN VIVO, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 11. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 12. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 13. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 14. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 15. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLAMMATORY DISEASES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 16. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY MICROBIAL DISEASES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 17. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 18. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY HOSPITALS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 19. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 20. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 21. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 22. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 23. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 24. AMERICAS MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 25. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 26. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 27. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 28. ARGENTINA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 29. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 30. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 31. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 32. BRAZIL MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 33. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 34. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 35. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 36. CANADA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 37. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 38. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 39. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 40. MEXICO MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 41. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 42. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 43. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 44. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 45. UNITED STATES MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 46. CALIFORNIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 47. CALIFORNIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 48. CALIFORNIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 49. CALIFORNIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 50. FLORIDA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 51. FLORIDA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 52. FLORIDA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 53. FLORIDA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 54. ILLINOIS MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 55. ILLINOIS MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 56. ILLINOIS MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 57. ILLINOIS MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 58. NEW YORK MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 59. NEW YORK MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 60. NEW YORK MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 61. NEW YORK MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 62. OHIO MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 63. OHIO MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 64. OHIO MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 65. OHIO MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 66. PENNSYLVANIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 67. PENNSYLVANIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 68. PENNSYLVANIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 69. PENNSYLVANIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 70. TEXAS MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 71. TEXAS MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 72. TEXAS MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 73. TEXAS MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 74. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 75. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 76. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 77. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 78. ASIA-PACIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 79. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 80. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 81. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 82. CHINA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 83. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 84. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 85. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 86. INDIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 87. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 88. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 89. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 90. INDONESIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 91. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 92. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 93. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 94. JAPAN MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 95. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 96. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 97. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 98. MALAYSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 99. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 100. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 101. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 102. PHILIPPINES MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 103. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 104. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 105. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 106. SOUTH KOREA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 107. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 108. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 109. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 110. THAILAND MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 116. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 117. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 118. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 119. FRANCE MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 120. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 121. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 122. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 123. GERMANY MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 124. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 125. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 126. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 127. ITALY MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 128. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 129. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 130. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 131. NETHERLANDS MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 132. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 133. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 134. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 135. QATAR MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 136. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 137. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 138. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 139. RUSSIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 140. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 141. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 142. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 143. SAUDI ARABIA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 144. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 145. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 146. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 147. SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 148. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 149. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 150. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 151. SPAIN MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 152. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 153. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 154. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 155. UNITED ARAB EMIRATES MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 156. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY END-USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 157. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY INDICATION, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 158. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY PRODUCTION TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 159. UNITED KINGDOM MONOCLONAL ANTIBODIES MARKET SIZE, BY SOURCE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 160. GLOBAL MONOCLONAL ANTIBODIES MARKET: SCORES
TABLE 161. GLOBAL MONOCLONAL ANTIBODIES MARKET: BUSINESS STRATEGY
TABLE 162. GLOBAL MONOCLONAL ANTIBODIES MARKET: PRODUCT SATISFACTION
TABLE 163. GLOBAL MONOCLONAL ANTIBODIES MARKET: RANKING
TABLE 164. GLOBAL MONOCLONAL ANTIBODIES MARKET: MERGER & ACQUISITION
TABLE 165. GLOBAL MONOCLONAL ANTIBODIES MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 166. GLOBAL MONOCLONAL ANTIBODIES MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 167. GLOBAL MONOCLONAL ANTIBODIES MARKET: INVESTMENT & FUNDING
TABLE 168. GLOBAL MONOCLONAL ANTIBODIES MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 169. GLOBAL MONOCLONAL ANTIBODIES MARKET: LICENSE & PRICING
TABLE 170. GLOBAL MONOCLONAL ANTIBODIES MARKET: CONTACT DETAILS
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • AbbVie, Inc
  • AbGenomics
  • ADC Therapeutics
  • ALMAC Group
  • Amgen Inc.
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Idec Inc.
  • Bristol Myers Squibb
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GenScript Biotech Corporation
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis International AG
  • Novo Nordisk A/S
  • Pfizer Inc
  • Sanofi S.A.
  • Seagen Inc.
  • Shanghai Junshi Biosciences Co., Ltd.
  • Thermo Fisher Scientific, Inc
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll